Labcorp — Jul 30, 2026 release

$4.35, up 14.9% • Raised full-year enterprise revenue growth and adjusted EPS guidance: ◦ Annual revenue growth guidance of 5.4% to 6.3%; up 30 basis points at the midpoint ◦ Adjusted EPS range of $18.10 to $18.55; up 30 cents at the midpoint • Announced $1.0 billion increase in share repurchase authorization, bringing the remaining total authorization to $1.4 billion • Advanced Labcorp Oncology offerings in lung, colorectal, and prostate cancers, expanding access to screening, improving diagnosis, guiding treatment selection, and monitoring recurrence • Announced the launch of Marker by Labcorp™, a genetic health panel that provides consumers with personalized genetic insights BURLINGTON, N.C., July 30, 2026 – Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the second quarter ended June 30, 2026 and updated its full-year financial guidance. “Labcorp delivered another very strong quarter, with 6% revenue growth, significant margin expansion, and double-digit adjusted EPS growth reflecting continued momentum across the business,” said Adam Schechter, Chairman and CEO of Labcorp. “During the second quarter, we expanded our leadership in oncology and other high-growth specialty areas, strengthened our position as the partner of choice for health systems, biopharmaceutical companies, and regional/local laboratories, and advanced our use of technology to improve the